LONG-TERM RESULTS OF SECOND LINE ANTICANCER THERAPY OF METASTATIC COLORECTAL CANCER AND THEIR RELATIONSHIP WITH CLINICAL AND MORPHOLOGICAL CHARACTERISTICS


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, the actual problem in the treatment of patients with metastatic colorectal cancer is the search for significant prognostic and predictive factors. To date, the results of numerous studies allow to identify a number of such factors, but in most cases, the role of certain clinical and morphological characteristics remains significantly unproven. The article presents the results of univariate and multivariate analyses aimed to identification of significant predictors of survival of patients with metastatic colorectal cancer who have received a second line drug therapy within a framework of prospective study.

全文:

受限制的访问

作者简介

K. Vorontsova

FSBI “RORC n.a. N.N. Blokhin" of RMH

PhD, oncologist at the Department of Chemotherapy and Combined Therapy of Malignant Tumors Moscow

E. Chemoglazova

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

L. Rotobelskaya

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

G. Vyshinskaya

FSBI “RORC n.a. N.N. Blokhin" of RMH

Moscow

参考

  1. Schmoll H.J., Van Cutsem E., Stein A., Valentini V., Glimelius B., Haustermans K., Nordlinger B., van deVelde C.J., BalmanaJ., RegulaJ., Nagtegaal I.D., Beets-Tan R.G., Arnold D., Ciardiello F., Hoff P., Kerr D., Köhne C.H., Labianca R., Price T., Scheithauer W., Sobrero A., Tabernero J., Aderka D., Barroso S., Bodoky G., Douillard J.Y., El Ghazaly H., Gallardo J., Garin A., Glynne-Jones R., Jordan K., Meshcheryakov A., Papamichail D., Pfeiffer P., Souglakos I., Turhal S., Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. А personalized approach to clinical decision making. Ann. Oncol. 2012;23(10):2479-516.
  2. Köhne C.H., Cunningham D., Di Costanzo F., Glimelius B, Blijham G., Aranda E., Scheithauer W., Rougier P., Palmer M., Wils J., Baron B., Pignatti F., Schöffski P., Micheel S., Hecker H. Clinical determinants of survival in patients with 5-fluoroura-cil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann. Oncol. 2002;13(2):308-17.
  3. Seymour M.T., Thompson L.C., Wasan H.S., Middleton G., Brewster A.E., Shepherd S.F., O'Mahony M.S., Maughan T.S., Parmar M., Langley R.E.; FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377( 9779):1749-59.
  4. Sorbye H., Köhne C.H., Sargent D.J., Glimelius B. Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Ann. Oncol. 2007;18(10):1666-72.
  5. Zacharakis M., Xynos I.D., Lazaris A., Smaro T., Kosmas C., Dokou A., Felekouras E., Antoniou E., Polyzos A., Sarantonis J., Syrios J., Zografos G., Papalambros A., Tsavaris N. Predictors of Survival in Stage IV Metastatic Colorectal Cancer. Anticancer Res. 2010;30(2):653-60.
  6. RothA.,KlingbielD., YanP., FioccaR.,DelorenziM., Labianca R., Cunningham D., Van Cutsem E., Bosman F., Tejpar S. Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J. Clin. Oncol. 2010;28(15):suppl 3504.
  7. Adams R.A., Meade A.M., Seymour M.T., Wilson R.H., Madi A., Fisher D., Kenny S.L., Kay E., Hodgkinson E., Pope M., Rogers P., Wasan H., Falk S., Gollins S., Hickish T., Bessell E.M., Propper D., Kennedy M.J., Kaplan R., Maughan T.S. MRC COIN Trial Investigators. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011;12(7):642-53.
  8. Russo A., Bazan V., Agnese V., Rodolico V., Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann. Oncol. 2005;(suppl 4):iv44-49.
  9. De Roock W., Claes B., Bernasconi D., De Schutter J., Biesmans B., Fountzilas G., Kalogeras K.T., Kotoula V., Papamichael D., Laurent-Puig P., Penault-Llorca F., Rougier P., Vincenzi B., Santini D., Tonini G., Cappuzzo F., Frattini M., Molinari F., Saletti P., De Dosso S., Martini M., Bardelli A., Siena S., Sartore-Bianchi A., Tabernero J., Macarulla T.,DiFiore F., Gangloff A.O.,Ciardiello F., Pfeiffer P., Qvortrup C., Hansen T.P., Van Cutsem E., Piessevaux H., Lambrechts D., Delorenzi M., Tejpar S. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11(8):753-62.
  10. Barault L., Veyrie N., Jooste V., Lecorre D., Chapusot C., Ferraz J.M., Liеvre A., Cortet M., Bouvier A.M., Rat P., Roignot P., Faivre J., Laurent-Puig P., Piard F. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int. J. Cancer. 2008;122(10):2255-9.
  11. Tol J., Nagtegaal I.D., Punt C.J.A. BRAF Mutation in Metastatic Colorectal Cancer. N. Engl. J. Med. 2009;361:98-9.
  12. Waring P., Tie J., Maru D., Karapetis C.S. RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer. Clin. Colorectal. Cancer. 2015 Nov 11. pii: S1533-0028(15)00145-0. doi: 10.1016/j. clcc.2015.10.006.
  13. Lech G., Slotwinski R., Slodkowski M., Krasnodеbski I.W. Colorectal cancer tumour markers and biomarkers: Recent therapeutic advances. World J. Gastroenterol. 2016;22(5):1745-55.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2016
##common.cookie##